Filing Details

Accession Number:
0001179110-18-012205
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2018-10-16 16:17:57
Reporting Period:
2018-10-05
Accepted Time:
2018-10-16 16:17:57
Original Submission Date:
2018-10-09
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1235007 Endocyte Inc ECYT Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1633299 Katherine Parker 3000 Kent Ave, Suite A1-100
West Lafayette IN 47906
Vp Of Human Resources No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-10-05 6,771 $15.55 70,869 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,200 Indirect By trust
Footnotes
  1. Represents the sale of 6,771 shares in multiple transactions ranging in price from $15.1300 to $15.9200, resulting in a weighted-average sale price per share of $15.5540. The 6,771 shares were sold to cover taxes, commissions and fees associated with the October 4, 2018 settlement of 15,000 restricted stock units in the form of Company common stock on a one-for-one basis. The shares were sold pursuant to a written plan as specified in Rule 10b5-1(c) of the Securities Exchange Act of 1934.
  2. Includes 520 shares acquired under the Endocyte, Inc. 2010 Employee Stock Purchase Plan on June 15, 2018 that were inadvertently omitted from the amount of securities beneficially owned by the reporting person as reported on the Form 4 filed by the reporting person on October 9, 2018.